Nohla Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nohla Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11043
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nohla Therapeutics Inc (Nohla Therapeutics) focuses on the development of universal, off-the-shelf cell therapies for the treatment of hematologic malignancies and other critical diseases. The company develops clinical, preclinical and discovery programs based on its proprietary notch ligand technology platform. Its lead product candidate, dilanubicel, which is in two Phase 2 clinical trials that provides the functional support of bone marrow until patient’s immune system recovers. The company also carries out preclinical programs in the areas of immune tolerance and other diseases. Nohla Therapeutics is headquartered in Seattle, Washington, the US.

Nohla Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Nohla Therapeutics Raises Additional USD11 Million in Second Tranche of Series B Venture Financing 10
Nohla Therapeutics Raises USD45 Million in Series B Venture Financing 12
Nohla Therapeutics Raises USD43.5 Million in Series A Venture Financing 14
Licensing Agreements 15
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 15
Equity Offering 16
Nohla Therapeutics Raises USD21 Million in Private Financing Round 16
Acquisition 17
Life Corporation Services to Sell Minority Stake in Nohla Therapeutics 17
Nohla Therapeutics Inc – Key Competitors 18
Nohla Therapeutics Inc – Key Employees 19
Nohla Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Jul 30, 2018: Nohla Therapeutics Announces Hiring of Dr. Sarah Noonberg as Chief Medical Officer and Appointment of Dr. Colleen Delaney as Chief Scientific Officer 21
Apr 23, 2018: Nohla Therapeutics Announces Hiring of Gary Christianson as Chief Operating Officer 22
Jan 04, 2018: Nohla Therapeutics Announces Hiring of Jim Johnson as Chief Financial Officer 23
Feb 02, 2017: Nohla Therapeutics Appoints Kathleen Fanning as President and Chief Executive Officer 24
Product Approvals 25
Jan 23, 2018: Nohla Therapeutics Granted Orphan Drug Designation in the European Union for NLA101 in the Treatment of Hematopoietic Stem Cell Transplantation 25
Clinical Trials 26
Feb 13, 2018: Nohla Therapeutics Initiates Global LAUNCH Phase 2 Trial of NLA101 in Patients with AML 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nohla Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Nohla Therapeutics Raises Additional USD11 Million in Second Tranche of Series B Venture Financing 10
Nohla Therapeutics Raises USD45 Million in Series B Venture Financing 12
Nohla Therapeutics Raises USD43.5 Million in Series A Venture Financing 14
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 15
Nohla Therapeutics Raises USD21 Million in Private Financing Round 16
Life Corporation Services to Sell Minority Stake in Nohla Therapeutics 17
Nohla Therapeutics Inc, Key Competitors 18
Nohla Therapeutics Inc, Key Employees 19

List of Figures
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nohla Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Nohla Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Starpharma Holdings Ltd (SPL):製薬・医療:M&Aディール及び事業提携情報
    Summary Starpharma Holdings Ltd (Starpharma) is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company’s developmen …
  • Galapagos NV:企業のM&A・事業提携・投資動向
    Galapagos NV - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Galapagos NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Imugene Ltd (IMU):製薬・医療:M&Aディール及び事業提携情報
    Summary Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which researches and develops vaccines in the area of immune-oncology. The company focuses on developing immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various t …
  • Suelopetrol CA SACA:企業の戦略的SWOT分析
    Suelopetrol CA SACA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Turkiye Halk Bankasi AS:企業の戦略・SWOT・財務分析
    Turkiye Halk Bankasi AS - Strategy, SWOT and Corporate Finance Report Summary Turkiye Halk Bankasi AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Global Bioenergies SA (ALGBE):企業の財務・戦略的SWOT分析
    Global Bioenergies SA (ALGBE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Tenaga Nasional Bhd (TENAGA):企業の財務・戦略的SWOT分析
    Tenaga Nasional Bhd (TENAGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Kuros Biosciences Ltd (KURN)-製薬・医療分野:企業M&A・提携分析
    Summary Kuros Biosciences Ltd (Kuros Biosciences) is a biotechnology company that develops products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specificall …
  • Kirin Holdings Co Ltd:企業の戦略・SWOT・財務情報
    Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Optus Inc:企業の戦略的SWOT分析
    Optus Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Swadeshi Industrial Works Plc:企業の戦略・SWOT・財務分析
    Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report Summary Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Impresa Pizzarotti & C. S.p.A.:企業の戦略・SWOT・財務情報
    Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • H2O Retailing Corp:企業の戦略・SWOT・財務分析
    H2O Retailing Corp - Strategy, SWOT and Corporate Finance Report Summary H2O Retailing Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Orlando Utilities Commission:発電所・企業SWOT分析
    Orlando Utilities Commission - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Impel NeuroPharma Inc:医療機器:M&Aディール及び事業提携情報
    Summary Impel NeuroPharma Inc (Impel) is a clinical-stage biotechnology company that which develops intranasal drug treatments for central nervous system disorders. The company’s product pipeline includes INP104, INP103, INP102, INP101, INP105, and INP106. It also develops Precision Olfactory Delive …
  • Skechers U.S.A., Inc. (SKX):企業の財務・戦略的SWOT分析
    Skechers U.S.A., Inc. (SKX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • ICF International, Inc.:戦略・SWOT・企業財務分析
    ICF International, Inc. - Strategy, SWOT and Corporate Finance Report Summary ICF International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nido Petroleum Ltd:企業の戦略的SWOT分析
    Nido Petroleum Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Taita Chemical Co, Ltd (1309):企業の財務・戦略的SWOT分析
    Taita Chemical Co, Ltd (1309) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Quantum Genomics SA (ALQGC):企業の財務・戦略的SWOT分析
    Summary Quantum Genomics SA (Quantum Genomics) is a biopharmaceutical company which develops novel medicines in the field of cardiovascular diseases. The company develops drugs to treat high blood pressure and heart failure. Its research programs are based on the Brain Aminopeptidase A Inhibition (B …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆